Subtly impaired humoral immunity predisposes to frequently recurring genital herpes simplex virus type 2 infection and herpetic neuralgia

Journal of Infectious Diseases

Volumn 194, Issue 5, 2006, Pages 571-578

  Seppänen, Mikko ^a   Meri, Seppo ^b   Notkola, Irma Leena ^c   Seppälä, Ilkka J T ^b   Hiltunen Back, Eija ^a   Sarvas, Heikki ^b   Lappalainan, Maija ^b   Välimaa, Hannamari ^b   Palikhe, Anil ^b   Valtonen, Ville V ^a   Lokki, Marja Liisa ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; THROMBOSPONDIN; VIRUS ANTIBODY;

ADULT; ALLOTYPE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CASE CONTROL STUDY; COMPLEMENT CLASSICAL PATHWAY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPIDEMIC; FEMALE; GENITAL HERPES; GENOTYPE; HAPLOTYPE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMORAL IMMUNITY; IMMUNOGENETICS; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTECTION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT INFECTION; RISK FACTOR; TH1 CELL;

ADULT; ANTIBODY FORMATION; B-LYMPHOCYTES; CASE-CONTROL STUDIES; COMPLEMENT C4; COMPLEMENT FIXATION TESTS; DISEASE SUSCEPTIBILITY; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEURALGIA; RECURRENCE; REFERENCE VALUES;

EID: 33748036056     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/506477     Document Type: Article

References (49)

1. Patel R, Boselli F, Cairo I, Barnett G, Price M, Wulf HC. Patients' perspectives on the burden of recurrent genital herpes. Int J STD AIDS 2001; 12:640-5.
2. Whitley RJ, Miller RL. Immunologic approach to herpes simplex virus. Viral Immunol 2001; 14:111-8.
3. Posavad CM, Koelle DM, Corey L. Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nat Med 1998; 4:381-2.
4. Parr MB, Parr EL. Vaginal immunity in the HSV-2 mouse model. Int Rev Immunol 2003; 22:43-63.
5. Duerst RJ, Morrison LA. Innate immunity to herpes simplex virus type 2. Viral Immunol 2003; 16:475-90.
6. Novak N, Peng W. Dancing with the enemy: the interplay of herpes simplex virus with dendritic cells. Clin Exp Immunol 2005; 142:405-10.
7. Cunningham AL, Merigan TC. Gamma interferon production appears to predict time of recurrence of herpes labialis. J Immunol 1983; 130: 2397-400.
8. Spruance SL, Evans TG, McKeough MB, et al. Th1/Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res 1995; 28:39-55.
9. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16:96-113.
10. Chee AV, Roizman B. Herpes simplex virus 1 gene products occlude the interferon signaling pathway at multiple sites. J Virol 2004; 78:4185-96.
11. Corey L, Reeves WC, Holmes KK. Cellular immune response in genital herpes simplex virus infection. N Engl J Med 1978; 299:986-91.
12. Mathiesen T, Persson MA, Sundqvist VA, Wahren B. Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus. Clin Exp Immunol 1988; 72:211-5.
13. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002; 35(Suppl 2):S173-82.
14. Lubinski JM, Jiang M, Hook L, et al. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo. J Virol 2002;76:9232-41.
15. Johansson PJ, Hallberg T, Oxelius VA, Grubb A, Blomberg J. Human immunoglobulin class and subclass specificity of Fc receptors induced by herpes simplex virus type 1. J Virol 1984;50:796-804.
16. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5:981-6.
17. Armour KL, Atherton A, Williamson LM, Clark MR. The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochem Soc Trans 2002; 30:495-500.
18. Seppänen M, Suvilehto J, Lokki M-L, et al. Immunoglobulins and complement factor C4 in adult rhinosinusitis. Clin Exp Immunol 2006; 145:219-27.
19. Lekstrom-Himes JA, Hohman P, Warren T, et al. Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. J Infect Dis 1999; 179:1077-85.
20. dbMHC. Available at: http://www.ncbi.nlm.nih.gov/projects/mhc/ihwg.fcgi? ID=9&cmd=PRJOV. Accessed 25 April 2006.
21. Seppänen M, Lokki M-L, Timonen T, et al. Complement C4 deficiency and HLA homozygosity in patients with frequent intraoral herpes simplex virus type 1 infections. Clin Infect Dis 2001; 33:1604-7.
22. Sarnesto A. Monoclonal antibodies reacting with isotypic and/or allotypic determinants of human IgG. Med Biol 1983;61:126-32.
23. Seppala IJ, Routonen N, Sarnesto A, Mattila PA, Makela O. The percentages of six immunoglobulin isotypes in human antibodies to tetanus toxoid: standardization of isotype-specific second antibodies in solid-phase assay. Eur J Immunol 1984; 14:868-75.
24. Koskinen P, Vuorinen T, Meurman O. Influenza A and B virus IgG and IgM serology by enzyme immunoassays. Epidemiol Infect 1987; 99:55-64.
25. Seppala IJ, Sarvas H, Makela O. Low concentrations of Gm allotypic subsets G3 mg and G1 mf in homozygotes and heterozygotes. J Immunol 1993; 151:2529-37.
26. Marcus D, Alper CA. Methods for allotyping complement proteins. In: Rose NR, Friedman H, Fahey JL, eds. Manual of clinical laboratory immunology. 3rd ed. Washington DC: American Society for Microbiology, 1996:185-96.
27. Barba GM, Braun-Heimer L, Rittner C, Schneider PM. A new PCR-based typing of the Rodgers and Chido antigenic determinants of the fourth component of human complement. Eur J Immunogenet 1994; 21:325-39.
28. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-89.
29. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-9.
30. Kapadia A, Gupta S, Good RA, Day NK. Familial herpes simplex infection associated with activation of the complement system. Am J Med 1979; 67:122-6.
31. Mikloska Z, Sanna PP, Cunningham AL. Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J Virol 1999; 73:5934-44.
32. Kohl S, Charlebois ED, Sigouroudinia M, et al. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J Infect Dis 2000; 181:335-9.
33. Masci S, De Simone C, Famularo G, et al. Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study. Immunopharmacol Immunotoxicol 1995; 17:33-47.
34. Nagashunmugam T, Lubinski J, Wang L, et al. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 1998; 72:5351-9.
35. Beasley KL, Cooley GE, Kao GF, Lowitt MH, Burnett JW, Aurelian L. Herpes simplex vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency. J Am Acad Dermatol 1997; 37:860-3.
36. Witt MD, Torno MS, Sun N, Stein T. Herpes simplex virus lymphadenitis: case report and review of the literature. Clin Infect Dis 2002; 34:1-6.
37. Cunningham-Rundles C, Radigan L, Knight AK, Zhang L, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune deficiency. J Immunol 2006; 176:1978-87.
38. Binstadt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003; 111:697-703.
39. Hashido M, Kawana T. Herpes simplex virus-specific IgM, IgA and IgG subclass antibody responses in primary and nonprimary genital herpes patients. Microbiol Immunol 1997; 41:415-20.
40. Bindon CI, Hale G, Bruggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168:127-42.
41. Clark MR. IgG effector mechanisms. Chem Immunol 1997; 65:88-110.
42. Pan Q, Hammarstrom L. Molecular basis of IgG subclass deficiency. Immunol Rev 2000; 178:99-110.
43. Norose K, Yano A, Zhang XM, Blankenhorn E, Heber-Katz E. Mapping of genes involved in murine herpes simplex virus keratitis: identification of genes and their modifiers. J Virol 2002; 76:3502-10.
44. Holdsworth SR, Kitching AR, Tipping PG. Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int 1999;55:1198-216.
45. McKenna DB, Neill WA, Norval M. Herpes simplex virus-specific immune responses in subjects with frequent and infrequent orofacial recrudescences. Br J Dermatol 2001; 144:459-64.
46. Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 2004; 6:401-10.
47. Verschoor A, Brockman MA, Gadjeva M, Knipe DM, Carroll MC. Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J Immunol 2003; 171:5363-71.
48. Friedman HM. Keratin, a dual role in herpes simplex virus pathogenesis. J Clin Virol 2006;35:103-5.
49. Larsen CE, Alper CA. The genetics of HLA-associated disease. Curr Opin Immunol 2004; 16:660-7.